Replies to post #682097 on NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

NWBO is the 8 track cassette of cancer vaccines IMO
Placebo was better than DCVAX in PFS

One of the leading contenders in the race for a brain tumor vaccine is MimiVax’s SurVaxM. This vaccine candidate targets survivin, a protein that is overexpressed in cancer cells and plays a crucial role in tumor growth and survival. SurVaxM is administered after surgery and radiotherapy when the tumor burden is low, and the immune system is more responsive. The vaccine is given subcutaneously every two weeks for four doses, followed by a maintenance dose every eight weeks thereafter.

The results from MimiVax’s phase 2a trial in newly diagnosed glioblastomas (GBMs) are encouraging. When used as an add-on to standard therapy, SurVaxM demonstrated a median overall survival of 28.4 months from diagnosis

[User-840664]

Same FDA that took a hard PASS on DCVAX

The FDA has granted fast track designation to the investigational vaccine SurVaxM for the treatment of patients with newly diagnosed glioblastoma.1

SurVaxM is a first-of-its-kind immunotherapy that stimulates the immune system to attack survivin, which is present in 95% of glioblastomas. Immune assays have shown that SurVaxM generates survivin-specific CD8-positive T cells, resulting in anti-tumor antibody/immunoglobulin G titers that are associated with survival.

PS "Newly Diagnosed" is the best way to go.
Recurrent or progressive glioblastoma is a tiny market and very hard to treat at such a late stage.
https://www.onclive.com/view/fda-grants-fast-track-designation-to-survaxm-in-newly-diagnosed-glioblastoma